AMGN

Amgen price target raised by Jefferies to $410 after positive Sjögren's data

Amgen Stock Gains After Announcing Positive Phase 3 Sjögren’s Disease Trial Results

Canaccord reiterates Amgen stock Hold rating on pipeline win

Jefferies raises Amgen stock price target on drug trial success

Amgen, Vicor among market cap stock movers on Tuesday

Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data

Amgen's autoimmune drug succeeds in late-stage trial

Stocks making the biggest moves midday: Lennar, Capri, Vicor, Amgen & more

Amgen stock surges on positive Sjögren’s trial results

Amgen Boasts Success In Sjogren's; Shares Bound Higher

Amgen Drug May Offer Sjögren’s Patients First Effective Therapy

Amgen posts trial win for Sjögren's disease drug (AMGN:NASDAQ)

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE

Morgan Stanley flags Amgen's edge after heart-drug rival stumbles

Veeva Expands Amgen Partnership With Global Vault CRM Rollout Plan